✉ Email this page to a colleague
« Back to Dashboard
AFQ056 is an investigational drug.
There have been 25 clinical trials for AFQ056. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2011.
The most common disease conditions in clinical trials are Parkinson Disease, Dyskinesias, and Syndrome. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and Yale University.
Recent Clinical Trials for AFQ056
|Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant||Yale University||Early Phase 1|
|Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056||National Institute on Drug Abuse (NIDA)||Phase 1|
|Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056||Novartis Pharmaceuticals||Phase 1|